David Lebowitz
Stock Analyst at Citigroup
(4.32)
# 363
Out of 5,147 analysts
119
Total ratings
59.77%
Success rate
14.65%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Maintains: Buy | $69 → $84 | $81.15 | +3.51% | 14 | Sep 3, 2025 | |
| CYTK Cytokinetics | Maintains: Buy | $77 → $84 | $62.22 | +35.00% | 4 | Sep 2, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Buy | $56 → $48 | $30.09 | +59.52% | 2 | Aug 20, 2025 | |
| SDGR Schrödinger | Downgrades: Neutral | $35 → $20 | $12.06 | +65.84% | 10 | Aug 15, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $243 → $290 | $233.50 | +24.20% | 14 | Aug 8, 2025 | |
| INCY Incyte | Maintains: Buy | $88 → $103 | $101.27 | +1.71% | 6 | Jul 30, 2025 | |
| VKTX Viking Therapeutics | Maintains: Neutral | $31 → $38 | $33.84 | +12.29% | 2 | Jul 24, 2025 | |
| COGT Cogent Biosciences | Maintains: Buy | $15 → $22 | $38.85 | -43.37% | 4 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $58 → $67 | $66.48 | +0.78% | 5 | Jul 11, 2025 | |
| EXEL Exelixis | Maintains: Buy | $45 → $56 | $44.06 | +27.10% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $10 | $13.78 | -27.43% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 → $1.5 | $1.30 | +15.38% | 6 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $45 | $68.19 | -34.01% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $68 | $92.29 | -26.32% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $432.00 | -11.57% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $61.73 | +55.52% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $4.99 | +140.48% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $332.92 | -50.74% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $26.97 | +44.61% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $21.71 | -3.27% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $9.41 | +4,203.93% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $3.42 | +309.36% | 2 | Oct 12, 2021 |
Ionis Pharmaceuticals
Sep 3, 2025
Maintains: Buy
Price Target: $69 → $84
Current: $81.15
Upside: +3.51%
Cytokinetics
Sep 2, 2025
Maintains: Buy
Price Target: $77 → $84
Current: $62.22
Upside: +35.00%
Celldex Therapeutics
Aug 20, 2025
Maintains: Buy
Price Target: $56 → $48
Current: $30.09
Upside: +59.52%
Schrödinger
Aug 15, 2025
Downgrades: Neutral
Price Target: $35 → $20
Current: $12.06
Upside: +65.84%
Ascendis Pharma
Aug 8, 2025
Maintains: Buy
Price Target: $243 → $290
Current: $233.50
Upside: +24.20%
Incyte
Jul 30, 2025
Maintains: Buy
Price Target: $88 → $103
Current: $101.27
Upside: +1.71%
Viking Therapeutics
Jul 24, 2025
Maintains: Neutral
Price Target: $31 → $38
Current: $33.84
Upside: +12.29%
Cogent Biosciences
Jul 18, 2025
Maintains: Buy
Price Target: $15 → $22
Current: $38.85
Upside: -43.37%
BridgeBio Pharma
Jul 11, 2025
Maintains: Buy
Price Target: $58 → $67
Current: $66.48
Upside: +0.78%
Exelixis
May 15, 2025
Maintains: Buy
Price Target: $45 → $56
Current: $44.06
Upside: +27.10%
May 9, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $13.78
Upside: -27.43%
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.30
Upside: +15.38%
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $68.19
Upside: -34.01%
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $92.29
Upside: -26.32%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $432.00
Upside: -11.57%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $61.73
Upside: +55.52%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $4.99
Upside: +140.48%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $332.92
Upside: -50.74%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $26.97
Upside: +44.61%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $21.71
Upside: -3.27%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $9.41
Upside: +4,203.93%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $3.42
Upside: +309.36%